Efficacy of combined low-dose ruxolitinib and cyclosporine in murine immune bone marrow failure

Haematologica. 2024 May 1;109(5):1603-1607. doi: 10.3324/haematol.2023.284358.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Bone Marrow Failure Disorders / drug therapy
  • Cyclosporine* / administration & dosage
  • Cyclosporine* / therapeutic use
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Mice
  • Nitriles*
  • Pyrazoles* / administration & dosage
  • Pyrazoles* / therapeutic use
  • Pyrimidines* / administration & dosage
  • Pyrimidines* / therapeutic use

Substances

  • ruxolitinib
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • Cyclosporine

Grants and funding

Funding: This research was supported by intramural funding from the National Heart, Lung, and Blood Institute (NHLBI).